Intermolecular Grows IP Portfolio to Over 700 U.S. Patents and Patent Applications
Intermolecular, Inc. (Nasdaq: IMI) today announced that its intellectual property (IP) portfolio has increased to 730 U.S. patents and patent applications. The company now owns or has exclusive rights to this portfolio which covers both its HPC™ innovation platform and the inventions resulting from deploying the platform for the benefit of its customers. The company filed 207 US patent applications in 2011, spanning innovations in semiconductor technology including advanced logic, DRAM, and Non-volatile Memory (NVM), as well as in clean-energy fields such as photovoltaics (PV), light-emitting diodes (LED), and energy-efficient glass.
Intermolecular's HPC (High Productivity Combinatorial) platform includes Tempus™ hardware, unique test-vehicle characterization methods, and Informatics analysis software. The HPC platform was developed using fundamental combinatorial processing technologies licensed from Symyx. The IP rights underlying these technologies were acquired by Intermolecular from Symyx as a result of Intermolecular's recent initial public offering of stock on the NASDAQ stock exchange.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.